Beijing Wantai Biological Pharmacy Enterprise (SHSE:603392) Full Year 2023 Results
Key Financial Results
- Revenue: CN¥5.51b (down 51% from FY 2022).
- Net income: CN¥1.25b (down 74% from FY 2022).
- Profit margin: 23% (down from 42% in FY 2022).
- EPS: CN¥0.99 (down from CN¥3.79 in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Beijing Wantai Biological Pharmacy Enterprise Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 41%. Earnings per share (EPS) also missed analyst estimates by 74%.
Looking ahead, revenue is forecast to grow 46% p.a. on average during the next 2 years, compared to a 23% growth forecast for the Biotechs industry in China.
Performance of the Chinese Biotechs industry.
The company’s shares are down 9.8% from a week ago.
Risk Analysis
What about risks? Every company has them, and we’ve spotted 3 warning signs for Beijing Wantai Biological Pharmacy Enterprise you should know about.
Valuation is complex, but we’re helping make it simple.
Find out whether Beijing Wantai Biological Pharmacy Enterprise is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
